Corrigendum to: Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials (Australian and New Zealand Journal of Psychiatry, (2019), 54, 1, (29-45), 10.1177/0004867419883341);Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials

Australian and New Zealand Journal of Psychiatry

Volumn 54, Issue 1, 2020, Pages 29-45

  Witt, Katrina ^a   Potts, Jennifer ^a,b   Hubers, Anna ^a,c   Grunebaum, Michael F ^d   Murrough, James W ^e   Loo, Colleen ^f   Cipriani, Andrea ^a,b   Hawton, Keith ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WARNEFORD HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

depression; esketamine; ketamine; suicidal ideation; Suicide

Indexed keywords

ESCITALOPRAM; ESKETAMINE; FENTANYL; KETAMINE; METHOHEXITAL; MIDAZOLAM; PLACEBO; PROPOFOL; ANTIDEPRESSANT AGENT;

ALL CAUSE MORTALITY; ANXIETY DISORDER; AUTOMUTILATION; BIPOLAR DEPRESSION; BOLUS INJECTION; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS; MOOD DISORDER; REVIEW; SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; KETAMINE; SUICIDAL IDEATION;

EID: 85075147455     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867420928878     Document Type: Erratum

References (56)

1. Abdallah C, Fasula M, Kelmendi B, et al. (2012) Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. Journal of ECT 28: 157–161.
2. Alizadeh N, Maroufi A, Nasseri K, et al. (2015) Antidepressant effect of combined ketamine and electroconvulsive therapy on patients with major depressive disorder: A randomized trial. Iranian Journal of Psychiatry and Behavioral Sciences 9: e1578.
3. Ballard E, Luckenbaugh D, Richards E, et al. (2015) Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. Journal of Psychiatric Research 68: 68–73.
4. Bartoli F, Clerici M, Carrà G, (2017a) Antidepressant response and dissociative effects after ketamine treatment: Two sides of the same coin? Journal of Clinical Psychiatry 78: e1318.
5. Bartoli F, Riboldi I, Crocamo C, et al. (2017b) Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neuroscience and Biobehavioral Reviews 77: 232–236.
6. Bergfeld I, Mantione M, Figee M, et al. (2018) Treatment-resistant depression and suicidality. Journal of Affective Disorders 235: 362–367.
7. Berman A, (2018) Risk factors proximate to suicide and suicide risk assessment in the context of denied suicide ideation. Suicide and Life: Threatening Behavior 48: 340–352.
8. Berman A, Cappiello A, Anand A, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47: 351–354.
9. Burger J, Capobianco M, Lovern R, et al. (2016) A double-blind, randomized, placebo-controlled sub-dissociative dose ketamine pilot study in the treatment of acute depression and suicidality in a military emergency department setting. Military Medicine 181: 1195–1199.
10. Caddy C, Amit B, McCloud T, et al. (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews 9: CD011612.
11. Carroll R, Metcalfe C, Gunnell D, (2014) Hospital presenting self-harm and risk of fatal and non-fatal repetition: Systematic review and meta-analysis. PLoS ONE 9: e89944.
12. Cooper M, Rosenblat J, Cha D, et al. (2017) Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: A narrative review. World Journal of Biological Psychiatry 18: 410–423.
13. Crawford M, Thomas O, Khan N, et al. (2007) Psychosocial interventions following self-harm: Systematic review of their efficacy in preventing suicide. British Journal of Psychiatry 190: 11–17.
14. Daly E, Singh J, Fedgchin M, et al. (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry 75: 139–148.
15. DiazGranados N, Ibrahim L, Brutsche N, et al. (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 71: 1605–1611.
16. Feder A, Parides M, Murrough J, et al. (2014) Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry 71: 681–688.
17. Fond G, Loundou A, Rabu C, et al. (2014) Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology 231: 3663–3676.
18. Gálvez V, Li A, Huggins C, et al. (2018) Repeated intranasal ketamine for treatment-resistant depression–The way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology 32: 397–407.
19. Gálvez V, Nikolin S, Ho K-A, et al. (2017) Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial. Comprehensive Psychiatry 73: 31–34.
20. Geulayov G, Kapur N, Turnbull P, et al. (2016) Epidemiology and trends in non-fatal self-harm in three centres in England, 2000–2012: Findings from the Multicentre Study of Self-harm in England. BMJ Open 6: e010538.
21. Gorlyn M, Keilp J, Burke A, et al. (2015) Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: Paroxetine vs. bupropion. Psychiatry Research 225: 407–412.
22. Griffiths J, Zarate C, Jr Rasimas J, (2014) Existing and novel biological therapeutics in suicide prevention. American Journal of Preventive Medicine 47: S195–S203.
23. Hawton K, Witt K, Taylor Salisbury T, et al. (2016a) Psychosocial interventions for self-harm in adults. Cochrane Database of Systematic Reviews 5: CD012189.
24. Hawton K, Witt K, Taylor Salisbury T, et al. (2016b) Psychosocial interventions following self-harm in adults: A systematic review and meta-analysis. Lancet Psychiatry 3: 740–750.
25. Higgins J, Altman D, Gøtzsche P, et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. British Medical Journal 343: d5928.
26. Hubers A, Moaddine S, Peersmann S, et al. (2018) Suicidal ideation and subsequent completed suicide in both psychiatric and non-psychiatric populations: A meta-analysis. Epidemiology and Psychiatric Sciences 27: 186–198.
27. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37: 1526–1533.
28. Jankauskas V, Necyk C, Chue J, et al. (2018) A review of ketamine’s role in ECT and non-ECT settings. Neuropsychiatric Disease and Treatment 14: 1437–1450.
29. Keilp J, Ellis S, Gorlyn M, et al. (2018) Suicidal ideation declines with improvement in the subjective symptoms of major depression. Journal of Affective Disorders 227: 65–70.
30. Lai R, Katalinic N, Glue P, et al. (2014) Pilot dose-response trial of I.V. ketamine in treatment-resistant depression. World Journal of Biological Psychiatry 15: 579–584.
31. Lally N, Nugent A, Luckenbaugh D, et al. (2014) Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Translational Psychiatry 14: e469.
32. Lapidus K, Levitch C, Perez A, et al. (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry 76: 970–976.
33. Li C-T, Chen M-H, Lin W-C, et al. (2016) The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study. Human Brain Mapping 37: 1080–1090.
34. Luckenbaugh D, Niciu M, Ionescu D, et al. (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders 159: 56–61.
35. McCloud T, Caddy C, Jochim J, et al. (2015) Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database of Systematic Reviews 9: CD011611.
36. Malhi G, Bassett D, Boyce P, et al. (2015) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry 49: 1087–1206.
37. Naughton M, Clarke G, O’Leary O, et al. (2014) A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use, and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders 156: 24–35.
38. Ochs-Ross R, Daly E, Zhang Y, et al. (2019) Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression. European Neuropsychopharmacology 29: S355–S356.
39. Phillips J, Birmingham M, Hatchard T, et al. (2017) Acute and prolonged antidepressant effects of ketamine in treatment-resistant depression. Neuropsychopharmacology 42: S159–S160.
40. Popova V, Daly E, Trivedi M, et al. (2018) Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression. Biological Psychiatry 83: S390.
41. Reinstatler L, Youssef N, (2015) Ketamine as a potential treatment for suicidal ideation: A systematic review of the literature. Drugs in R & D 15: 37–43.
42. Rodriguez C, Kegeles L, Levinson A, et al. (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology 38: 2475–2483.
43. Sanacora G, Frye M, McDonald W, et al. (2017) A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74: 399–405.
44. Schünemann H, Brozek J, Guyatt G, et al. (2013) GRADE handbook for grading quality of evidence and strength of recommendations. Available at: https://gdt.gradepro.org/app/handbook/handbook.html. Accessed 11 October, 2019.
45. Short B, Fong J, Galvez V, et al. (2018) Side-effects associated with ketamine use in depression: A systematic review. Lancet Psychiatry 5: 65–78.
46. Singh I, Morgan C, Curran V, et al. (2017) Ketamine treatment for depression: Opportunities for clinical innovation and ethical foresight. Lancet Psychiatry 4: 419–426.
47. Singh J, Fedgchin M, Daly E, et al. (2016) A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. American Journal of Psychiatry 173: 816–826.
48. Sos P, Klirova M, Novak T, et al. (2013) Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinology Letters 34: 287–293.
49. Su T-P, Chen M-H, Li C-T, et al. (2017) Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42: 2482–2492.
50. Wilkinson S, Ballard E, Bloch M, et al. (2018) The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. American Journal of Psychiatry 175: 150–158.
51. Witt K, Cipriani A, Potts J, et al. (2017) Ketamine for suicidality in adults: A systematic review and meta-analysis. PROSPERO CRD42017070591. Available at: www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017070591 (accessed 11 October 2019).
52. Xu Y, Hackett M, Carter G, et al. (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology 19: 1–15.
53. Yoosefi A, Sepehri A, Kargar M, et al. (2014) Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder. Journal of ECT 30: 15–21.
54. Zalsman G, Hawton K, Wasserman D, et al. (2016) Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry 3: 646–659.
55. Zarate C, Jr Singh J, Carlson P, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63: 856–864.
56. Zhong X, He H, Zhang C, et al. (2016) Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. Journal of Affective Disorders 201: 124–130.